UK MHRA aims to reduce anonymised patient reports sent to companies
This article was originally published in SRA
The UK Medicines and Healthcare products Regulatory Agency has implemented changes aimed at reducing the number of irrelevant anonymised single patient reports (ASPRs) – and their electronic equivalent, E2B individual case safety reports (ICSRs) – sent out to drug companies1.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.